Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial
Arthritis Res Ther. 2022 Nov 3;24(1):248.
doi: 10.1186/s13075-022-02940-5.